DE60019157D1 - Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit - Google Patents

Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit

Info

Publication number
DE60019157D1
DE60019157D1 DE60019157T DE60019157T DE60019157D1 DE 60019157 D1 DE60019157 D1 DE 60019157D1 DE 60019157 T DE60019157 T DE 60019157T DE 60019157 T DE60019157 T DE 60019157T DE 60019157 D1 DE60019157 D1 DE 60019157D1
Authority
DE
Germany
Prior art keywords
preparing
fatibility
diabetes
treatment
arylethanolamine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019157T
Other languages
English (en)
Other versions
DE60019157T2 (de
Inventor
Maxwell Lawrence
Alan Millar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60019157D1 publication Critical patent/DE60019157D1/de
Publication of DE60019157T2 publication Critical patent/DE60019157T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Glass Compositions (AREA)
DE60019157T 1999-12-11 2000-12-08 Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit Expired - Lifetime DE60019157T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9929297 1999-12-11
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process
PCT/GB2000/004697 WO2001042195A1 (en) 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Publications (2)

Publication Number Publication Date
DE60019157D1 true DE60019157D1 (de) 2005-05-04
DE60019157T2 DE60019157T2 (de) 2006-02-02

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019157T Expired - Lifetime DE60019157T2 (de) 1999-12-11 2000-12-08 Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit

Country Status (23)

Country Link
US (1) US6548523B2 (de)
EP (1) EP1235788B1 (de)
JP (1) JP4903964B2 (de)
KR (1) KR100683614B1 (de)
CN (1) CN1224609C (de)
AT (1) ATE292110T1 (de)
AU (1) AU769387B2 (de)
BR (1) BRPI0016187B1 (de)
CA (1) CA2394117C (de)
CZ (1) CZ303143B6 (de)
DE (1) DE60019157T2 (de)
ES (1) ES2236020T3 (de)
GB (1) GB9929297D0 (de)
HK (1) HK1045988B (de)
HU (1) HU229043B1 (de)
IL (1) IL149585A0 (de)
NO (1) NO323239B1 (de)
NZ (1) NZ518795A (de)
PL (1) PL200540B1 (de)
PT (1) PT1235788E (de)
TR (1) TR200201528T2 (de)
WO (1) WO2001042195A1 (de)
ZA (1) ZA200204585B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
TW201208667A (en) 2010-08-03 2012-03-01 Altherx Inc Pharmaceutical combinations
AR089957A1 (es) 2012-02-09 2014-10-01 Altherx Inc Combinaciones farmaceuticas, combinaciones sinergicas
EP3226849A4 (de) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von solabegron mit modifizierter freisetzung für symptome der unteren harnwege
DK3365321T3 (da) 2015-10-23 2024-01-15 B3Ar Therapeutics Inc Solabegron-zwitterion og anvendelser deraf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) * 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
KR100683614B1 (ko) 2007-02-16
HU229043B1 (hu) 2013-07-29
EP1235788B1 (de) 2005-03-30
ES2236020T3 (es) 2005-07-16
PL200540B1 (pl) 2009-01-30
BRPI0016187B1 (pt) 2016-08-02
US6548523B2 (en) 2003-04-15
IL149585A0 (en) 2002-11-10
ATE292110T1 (de) 2005-04-15
AU2191101A (en) 2001-06-18
PT1235788E (pt) 2005-08-31
ZA200204585B (en) 2003-12-31
DE60019157T2 (de) 2006-02-02
BR0016187A (pt) 2002-08-13
CA2394117A1 (en) 2001-06-14
CZ20022017A3 (cs) 2003-01-15
NO323239B1 (no) 2007-02-05
AU769387B2 (en) 2004-01-22
CZ303143B6 (cs) 2012-05-02
NZ518795A (en) 2004-02-27
HUP0203640A3 (en) 2003-08-28
HK1045988B (zh) 2005-07-15
KR20020061636A (ko) 2002-07-24
TR200201528T2 (tr) 2002-09-23
CN1409700A (zh) 2003-04-09
CN1224609C (zh) 2005-10-26
HUP0203640A2 (hu) 2003-02-28
GB9929297D0 (en) 2000-02-02
US20020198220A1 (en) 2002-12-26
JP4903964B2 (ja) 2012-03-28
NO20022758D0 (no) 2002-06-10
WO2001042195A1 (en) 2001-06-14
JP2003516383A (ja) 2003-05-13
CA2394117C (en) 2011-10-04
NO20022758L (no) 2002-07-01
EP1235788A1 (de) 2002-09-04
HK1045988A1 (en) 2002-12-20
PL356483A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
ATE446758T1 (de) Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
HUP0302475A2 (hu) Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával
ATE302751T1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
DK0468012T3 (da) 17beta-substituerede 4-aza-5alfa-androstan-3-on-derivater og fremgangsmåde til fremstilling deraf
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
FI895492A0 (fi) Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
DE60221283D1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE60019157D1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
ATE466569T1 (de) Nasale verabreichung von metoclopramid zur behandlung der gastroparese
DE602004006379D1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
NO20041378L (no) [[2-(Amino-3,4-diokso-1-cyklobuten-1-yl)amino]alkyl]-syrederivater for behandling av smerte
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE316374T1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
DE60108775D1 (de) Methode zur behandlung von schlaganfall
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
ATE219675T1 (de) Pharmazeutische zubereitung zur behandlung sogenannter rastloser beine
DE60218726D1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition